Vor Biopharma Inc. (VOR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 24.81M USD | Liabilities, Current |
| Cash and equivalents | 107.86M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 358.27M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $24.81M | $107.86M | $358.27M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $16.08M | $169.87M | $321.65M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $25.17M | $396.49M | $58.72M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $18.84M | $160.46M | $10.00M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $58.77M | $190.57M | $9.99M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $16.73M | $50.05M | $9.99M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $18.61M | $81.95M | $9.98M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.35M | $52.80M | $10.01M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $13.80M | $76.08M | $9.86M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $13.21M | $44.96M | $62.52M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $15.57M | $31.36M | $105.81M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $15.39M | $45.03M | $115.07M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $12.72M | $32.21M | $154.69M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $12.58M | $42.45M | $167.75M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $13.12M | $57.71M | $172.54M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $11.10M | $60.83M | $75.24M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $12.26M | $62.95M | $88.14M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $18.14M | $90.04M | $91.58M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $10.15M | $119.80M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $9.21M | $143.03M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $8.30M | $169.52M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $8.63M | $262.57M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $10.21M | $48.54M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $63.60M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $72.91M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |